Weight Loss Research, Health Insights & Smarter Choices
How Semaglutide Works as oral Weight Loss drugs and in Type 2 Diabetes For years, injectable medicines dominated the conversation around modern weight-loss treatment. That picture is changing rapidly in 2026. New oral weight loss drugs are now available, while researchers are also testing completely different approaches that target metabolism and skeletal muscle. One of … Read more
GLP-1 drug semaglutide may help heavy drinkers cut alcohol intake, reduce cravings, and offer a promising new addiction treatment.
Quitting GLP-1 drugs or a diet can cause weight regain—two strategies could help prevent Millions of Americans are now using GLP-Drugs such as Wegovy and Zepbound to lose weight and improve their health. These medicines can produce significant weight loss. But an important question remains: What happens when treatment stops? Research shows that weight regain … Read more
Weight Loss Drug Market Could Reach $150 Billion Globally | Morgan Stanley The race to develop obesity drugs is entering a new phase. For several years, the biggest question was simple: How much weight can a drug help people lose? Now the focus is changing. Doctors and researchers are increasingly asking whether patients can maintain … Read more
New study reveals lifelong use of weight-loss drugs like Mounjaro and Wegovy may be necessary A New Study Offers Clues About Why GLP-1 Weight Loss Varies Wegovy and Mounjaro have changed the way doctors approach obesity treatment. Yet one question remains common: why do some people lose much more weight than others on these medications? … Read more
Eli Lilly’s Retatrutide Hits Record Weight Loss, Challenges Surgery Efficacy | Whalesbook Retatrutide Is Producing Remarkable Weight-Loss Results The next generation of obesity medicines is moving quickly. One of the most closely watched candidates is retatrutide for weight loss, an experimental drug being developed by Eli Lilly. In May 2026, Lilly reported Phase 3 TRIUMPH-1 … Read more
FDA Approves New High-Dose of Wegovy HD 7.2 mg On March 19, 2026, the U.S. Food and Drug Administration approved Wegovy HD, a 7.2 mg once-weekly injectable dose of semaglutide, for certain adults with obesity or overweight plus at least one weight-related condition. The higher dose gives eligible patients another treatment option when clinically appropriate. … Read more
Foundayo(orforglipron) has moved from the clinical-trial stage into real-world U.S. obesity treatment. On April 1, 2026, the U.S. Food and Drug Administration approved Foundayo (orforglipron), an oral GLP-1 receptor agonist developed by Eli Lilly. It is approved for adults with obesity, or adults who are overweight and have at least one weight-related medical condition, when … Read more
GLP-1 drugs in 2026: More people without diabetes use drugs for weight loss GLP-1 medicines have changed how doctors approach obesity, type 2 diabetes and several related health problems. Drugs such as Wegovy, Ozempic and other GLP-1-based treatments can reduce appetite, improve blood sugar control and help many people lose significant amounts of weight. But … Read more